Q-omics provides the consensus-scored COMMD3-BMI1 profile across patient tissues and cancer cell-line models. COMMD3-BMI1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, COMMD3-BMI1 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, COMMD3-BMI1 RNA expression shows 15,275 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, HNSC, and THYM as cancer lineages where COMMD3-BMI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COMMD3-BMI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COMMD3-BMI1 survival associations across molecular data types. COMMD3-BMI1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COMMD3-BMI1 RNA expression–survival associations across cancer types. High COMMD3-BMI1 expression shows unfavorable associations in SCLC, LUAD, UVM, UCEC, READ and COAD. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for COMMD3-BMI1 RNA expression.
This table summarizes COMMD3-BMI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for COMMD3-BMI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COMMD3-BMI1 shows lower tumor expression in LUSC and higher tumor expression in HNSC, BRCA, CHOL, COAD and STAD. The HNSC box plot shows higher COMMD3-BMI1 RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .017).
This table shows molecular features associated with COMMD3-BMI1 in patient tissues and cancer cell lines. In patient samples, COMMD3-BMI1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, COMMD3-BMI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
